Mpox-Specific Neutralizing Antibodies up to 9 Months Following 1 or 2 Doses of Intradermal MVA-BN Vaccination in Sweden - Top-Institutions - MDSpire

Mpox-Specific Neutralizing Antibodies up to 9 Months Following 1 or 2 Doses of Intradermal MVA-BN Vaccination in Sweden

  • By

  • Carmen Espinosa-Gongora

  • Wanda Christ

  • Núria Mayola Danés

  • Claudia Eichler-Jonsson

  • Finn Filén

  • Elisabet Storgärd

  • Victor Westergren

  • Jonas Klingström

  • Sara Gredmark-Russ

  • Kari Johansen

  • Anna Mia Ekström

  • Klara Sondén

  • October 28, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Vaccinology

  • #2

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Immunology
    • Infectious Diseases
    • Vaccine Research

  • #3

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Sweden

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Public Health

  • #4

    University of Oxford
    University of Oxford

    Oxford, United Kingdom

    Key Differentiators

    • Vaccinology
    • Infectious Diseases
    • Immunology

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • HIV Research
    • Immunology

Original Source(s)

Mpox-Specific Neutralizing Antibodies up to 9 Months Following 1 or 2 Doses of Intradermal MVA-BN Vaccination in Sweden

  • by Carmen Espinosa-Gongora, Wanda Christ, Núria Mayola Danés, Claudia Eichler-Jonsson, Finn Filén, Elisabet Storgärd, Victor Westergren, Jonas Klingström, Sara Gredmark-Russ, Kari Johansen, Anna Mia Ekström, Klara Sondén

  • October 28, 2025

Related Content

Prevalence, risk factors, and perceptions of vaccination against reproductive tract infections among urban females in Delhi: a cross-sectional study

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic Plasmodium falciparum sporozoite challenge in mice

‘Patient autonomy’ has nothing to do with childhood vaccine policies